149 related articles for article (PubMed ID: 34114138)
21. Effect of antiglaucoma agents on short-term intraocular pressure fluctuations after intravitreal bevacizumab injections.
Shoeibi N; Ghosi Z; Jafari H; Omidtabrizi A
Int Ophthalmol; 2021 Mar; 41(3):1081-1090. PubMed ID: 33389369
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
23. Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre.
Kóthy P; Holló G
Int Ophthalmol; 2020 Feb; 40(2):377-383. PubMed ID: 31650353
[TBL] [Abstract][Full Text] [Related]
24. Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection.
Lam J; Luttrell I; Ding L; Rezaei K; Chao JR; Chee Y; Olmos De Koo LC; Wen JC
Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2489-2494. PubMed ID: 31388743
[TBL] [Abstract][Full Text] [Related]
25. Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection.
El Chehab H; Le Corre A; Agard E; Ract-Madoux G; Coste O; Dot C
Eur J Ophthalmol; 2013; 23(3):277-83. PubMed ID: 23161177
[TBL] [Abstract][Full Text] [Related]
26. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension.
Greig SL; Deeks ED
Drugs Aging; 2015 Mar; 32(3):251-60. PubMed ID: 25732405
[TBL] [Abstract][Full Text] [Related]
27. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab.
Theoulakis PE; Lepidas J; Petropoulos IK; Livieratou A; Brinkmann CK; Katsimpris JM
Klin Monbl Augenheilkd; 2010 Apr; 227(4):280-4. PubMed ID: 20408074
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the Use of Brinzolamide-Brimonidine Fixed Combination in Maximum Medical Therapy.
Tekeli O; Köse HC
Turk J Ophthalmol; 2022 Aug; 52(4):262-269. PubMed ID: 36017234
[TBL] [Abstract][Full Text] [Related]
29. Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial.
Fechtner RD; Myers JS; Hubatsch DA; Budenz DL; DuBiner HB
Eye (Lond); 2016 Oct; 30(10):1343-1350. PubMed ID: 27367743
[TBL] [Abstract][Full Text] [Related]
30. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
31. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.
Lusthaus JA; Goldberg I
Expert Opin Drug Saf; 2017 Sep; 16(9):1071-1078. PubMed ID: 28656780
[TBL] [Abstract][Full Text] [Related]
32. Brinzolamide-timolol fixed combination for the prevention of intraocular pressure elevation after phacoemulsification.
Georgakopoulos CD; Makri OE; Plotas P; Pharmakakis N
Clin Exp Ophthalmol; 2013; 41(7):662-7. PubMed ID: 23432730
[TBL] [Abstract][Full Text] [Related]
33. Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging.
Enz TJ; Bittner M; Tribble JR; Williams PA; Thiel MA; Schmid MK; Bachmann LM; Bochmann F
Transl Vis Sci Technol; 2022 Feb; 11(2):1. PubMed ID: 35103799
[TBL] [Abstract][Full Text] [Related]
34. Medical control of intraocular pressure with brinzolamide 1% after phacoemulsification.
Kir E; Cakmak H; Dayanir V
Can J Ophthalmol; 2008 Oct; 43(5):559-62. PubMed ID: 18982032
[TBL] [Abstract][Full Text] [Related]
35. A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004.
Feldman RM; Katz G; McMenemy M; Hubatsch DA; Realini T
Am J Ophthalmol; 2016 May; 165():188-97. PubMed ID: 26940161
[TBL] [Abstract][Full Text] [Related]
36. Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab.
Lee JW; Park H; Choi JH; Lee HJ; Moon SW; Kang JH; Kim YG
BMC Ophthalmol; 2016 May; 16():69. PubMed ID: 27245159
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of brimonidine in preventing intraocular pressure spikes following phacoemulsification in glaucoma patients.
Kandarakis A; Soumplis V; Karampelas M; Panos C; Kyriakos N; Baxevanakis A; Karagiannis D
Eur J Ophthalmol; 2010; 20(6):994-9. PubMed ID: 20544673
[TBL] [Abstract][Full Text] [Related]
38. Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy.
Yeom HY; Lee JH; Hong YJ; Seong GJ
J Ocul Pharmacol Ther; 2006 Jun; 22(3):176-81. PubMed ID: 16808678
[TBL] [Abstract][Full Text] [Related]
39. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
Goñi FJ;
Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
[TBL] [Abstract][Full Text] [Related]
40. Comparison of dorzolamide/timolol vs brinzolamide/brimonidine fixed combination therapy in the management of primary open-angle glaucoma.
Kozobolis V; Panos GD; Konstantinidis A; Labiris G
Eur J Ophthalmol; 2017 Mar; 27(2):160-163. PubMed ID: 27445072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
